{"title":"绘制肿瘤免疫景观:癌症免疫治疗中的单细胞RNA测序","authors":"Yingying Huang , Mao Zhang , Qiang Gao","doi":"10.1016/j.canlet.2025.218012","DOIUrl":null,"url":null,"abstract":"<div><div>Single-cell RNA sequencing (scRNA-seq) has emerged as a transformative technology for unraveling the cellular complexity and architecture of diseased tissues. By capturing the transcriptomic profiles of individual cells, scRNA-seq reveals intra-tumoral heterogeneity, distinct immune cell states, and dynamic intercellular interactions, making it particularly valuable in the study of the tumor immune microenvironment (TIME). In recent years, scRNA-seq has been widely adopted in both basic cancer research and clinical applications, advancing our understanding of tumor development, immune regulation, and therapy resistance. These advances have also driven the evolution of computational tools and analytical methods needed to interpret complex scRNA-seq datasets to support the development of precision diagnostics. This review systematically summarizes the core analytical workflows for scRNA-seq data, outlines best practices in data processing, and explores the emerging applications and challenges of this technology in TIME research and translational oncology<strong>.</strong></div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"633 ","pages":"Article 218012"},"PeriodicalIF":10.1000,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mapping the tumor immune landscape: single-cell RNA sequencing in cancer immunotherapy\",\"authors\":\"Yingying Huang , Mao Zhang , Qiang Gao\",\"doi\":\"10.1016/j.canlet.2025.218012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Single-cell RNA sequencing (scRNA-seq) has emerged as a transformative technology for unraveling the cellular complexity and architecture of diseased tissues. By capturing the transcriptomic profiles of individual cells, scRNA-seq reveals intra-tumoral heterogeneity, distinct immune cell states, and dynamic intercellular interactions, making it particularly valuable in the study of the tumor immune microenvironment (TIME). In recent years, scRNA-seq has been widely adopted in both basic cancer research and clinical applications, advancing our understanding of tumor development, immune regulation, and therapy resistance. These advances have also driven the evolution of computational tools and analytical methods needed to interpret complex scRNA-seq datasets to support the development of precision diagnostics. This review systematically summarizes the core analytical workflows for scRNA-seq data, outlines best practices in data processing, and explores the emerging applications and challenges of this technology in TIME research and translational oncology<strong>.</strong></div></div>\",\"PeriodicalId\":9506,\"journal\":{\"name\":\"Cancer letters\",\"volume\":\"633 \",\"pages\":\"Article 218012\"},\"PeriodicalIF\":10.1000,\"publicationDate\":\"2025-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0304383525005828\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304383525005828","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Mapping the tumor immune landscape: single-cell RNA sequencing in cancer immunotherapy
Single-cell RNA sequencing (scRNA-seq) has emerged as a transformative technology for unraveling the cellular complexity and architecture of diseased tissues. By capturing the transcriptomic profiles of individual cells, scRNA-seq reveals intra-tumoral heterogeneity, distinct immune cell states, and dynamic intercellular interactions, making it particularly valuable in the study of the tumor immune microenvironment (TIME). In recent years, scRNA-seq has been widely adopted in both basic cancer research and clinical applications, advancing our understanding of tumor development, immune regulation, and therapy resistance. These advances have also driven the evolution of computational tools and analytical methods needed to interpret complex scRNA-seq datasets to support the development of precision diagnostics. This review systematically summarizes the core analytical workflows for scRNA-seq data, outlines best practices in data processing, and explores the emerging applications and challenges of this technology in TIME research and translational oncology.
期刊介绍:
Cancer Letters is a reputable international journal that serves as a platform for significant and original contributions in cancer research. The journal welcomes both full-length articles and Mini Reviews in the wide-ranging field of basic and translational oncology. Furthermore, it frequently presents Special Issues that shed light on current and topical areas in cancer research.
Cancer Letters is highly interested in various fundamental aspects that can cater to a diverse readership. These areas include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal actively focuses on experimental therapeutics, particularly the advancement of targeted therapies for personalized cancer medicine, such as metronomic chemotherapy.
By publishing groundbreaking research and promoting advancements in cancer treatments, Cancer Letters aims to actively contribute to the fight against cancer and the improvement of patient outcomes.